These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 25898313)

  • 1. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
    Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
    Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity.
    Sunayama J; Sato A; Matsuda K; Tachibana K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Stem Cells; 2011 Sep; 29(9):1327-37. PubMed ID: 21793107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells.
    Daniele S; Sestito S; Pietrobono D; Giacomelli C; Chiellini G; Di Maio D; Marinelli L; Novellino E; Martini C; Rapposelli S
    ACS Chem Neurosci; 2017 Jan; 8(1):100-114. PubMed ID: 27797168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FoxO proteins or loss of functional p53 maintain stemness of glioblastoma stem cells and survival after ionizing radiation plus PI3K/mTOR inhibition.
    Firat E; Niedermann G
    Oncotarget; 2016 Aug; 7(34):54883-54896. PubMed ID: 27448972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme.
    Sestito S; Nesi G; Daniele S; Martelli A; Digiacomo M; Borghini A; Pietra D; Calderone V; Lapucci A; Falasca M; Parrella P; Notarangelo A; Breschi MC; Macchia M; Martini C; Rapposelli S
    Eur J Med Chem; 2015 Nov; 105():274-88. PubMed ID: 26498573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines.
    Kim D; Kwon W; Park S; Kim W; Park JK; Han JE; Cho GJ; Yun S; Han SH; Kim MO; Ryoo ZY; Choi SK
    Life Sci; 2022 Jan; 288():120170. PubMed ID: 34826438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
    Kojima K; Shimanuki M; Shikami M; Samudio IJ; Ruvolo V; Corn P; Hanaoka N; Konopleva M; Andreeff M; Nakakuma H
    Leukemia; 2008 Sep; 22(9):1728-36. PubMed ID: 18548093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
    Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
    PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.